No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Analysts at Morgan Stanley upgraded their recommendation for shares of consumer healthcare outfit Haleon.
To back up their move, they pointed to the company's leading exposure in defensive categories, as well as the now greater clarity on margin expansion.
Hence, the analysts said that they now saw a path towards a high single digit compound annual growth rate for its earnings per share between 2026-30 - which was ahead of its sector peers.
Combined with the uncertain macroeconomic backdrop, they judged the company's shares to be an "attractive defensive play".
They also hiked their target price for the shares from 400.0p to 425.0p.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.